Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

100%

5 of 5 completed trials have results

Key Signals

2 recruiting5 with results

Enrollment Performance

Analytics

Phase 1

3(42.9%)

Phase 2

3(42.9%)

Phase 3

1(14.3%)

7Total

Phase 1(3)

Phase 2(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07118891Phase 1Recruiting

Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause

Role: lead

NCT07108894Phase 1Recruiting

A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants

Role: lead

NCT04427501Phase 2Completed

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness

Role: collaborator

NCT04603651Unknown

Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19

Role: collaborator

NCT04634409Phase 2Completed

A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness

Role: collaborator

NCT04497987Phase 3Completed

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff

Role: collaborator

NCT04701658Phase 2Completed

A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Role: collaborator

NCT04411628Phase 1Completed

A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19

Role: collaborator

All 8 trials loaded